Capricor Therapeutics (NASDAQ:CAPR) Raised to Strong-Buy at LADENBURG THALM/SH SH

Capricor Therapeutics (NASDAQ:CAPR) was upgraded by research analysts at LADENBURG THALM/SH SH to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

Several other equities analysts have also recently commented on the stock. Roth Mkm reissued a “buy” rating and issued a $38.00 price target on shares of Capricor Therapeutics in a research report on Friday, May 15th. B. Riley Financial upped their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Piper Sandler reiterated an “overweight” rating and issued a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Capricor Therapeutics in a research note on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Capricor Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $50.30.

Capricor Therapeutics Price Performance

Shares of NASDAQ:CAPR opened at $26.44 on Thursday. The firm has a market capitalization of $1.53 billion, a PE ratio of -11.40 and a beta of 0.39. Capricor Therapeutics has a 1 year low of $4.30 and a 1 year high of $40.37. The firm’s 50-day moving average is $30.00 and its two-hundred day moving average is $28.41.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.04). Analysts expect that Capricor Therapeutics will post -0.75 EPS for the current fiscal year.

Insider Buying and Selling

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 25,000 shares of the stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $30.13, for a total value of $753,250.00. Following the transaction, the chief financial officer directly owned 8,223 shares in the company, valued at $247,758.99. This represents a 75.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Karimah Es Sabar sold 61,265 shares of the stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $30.17, for a total transaction of $1,848,365.05. The disclosure for this sale is available in the SEC filing. Insiders sold 173,429 shares of company stock valued at $5,329,440 over the last ninety days. 9.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Glenmede Trust Co. NA lifted its position in Capricor Therapeutics by 13.2% in the first quarter. Glenmede Trust Co. NA now owns 36,330 shares of the biotechnology company’s stock valued at $1,104,000 after acquiring an additional 4,240 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Capricor Therapeutics by 672.0% during the first quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock worth $12,631,000 after purchasing an additional 361,664 shares during the last quarter. Stempoint Capital LP grew its holdings in shares of Capricor Therapeutics by 110.6% during the first quarter. Stempoint Capital LP now owns 37,592 shares of the biotechnology company’s stock worth $1,143,000 after purchasing an additional 19,739 shares during the last quarter. Janus Henderson Group PLC purchased a new position in shares of Capricor Therapeutics during the first quarter worth about $687,000. Finally, Ally Bridge Group NY LLC acquired a new stake in shares of Capricor Therapeutics during the first quarter worth about $3,463,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.